Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming Soon – April 2019
Growth hormone is an endogenous hormone produced by the pituitary gland; a deficiency in its production or activity is characterized by short stature, decreased capacity for exercise, and unfavorable changes in cardiovascular function. There are a range of recombinant human growth hormone (somatropin) brands available for the treatment of hypopituitarism, short stature, and rare genetic disorders. Growth hormone product selection typically depends on the choice of delivery system and the support package offered by the manufacturer. This U.S. claims data analysis covers prescription patterns in growth hormone deficiency and other disorders for which recombinant growth hormone is approved for use.
Geographies United States
Real World data Longitudinal patient-level claims data analysis
Key Drugs Covered Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton
Key Analysis provided Brand/therapy usage across longitudinal patient sample Newly diagnosed patient analysis Treatment initiation and progression Line of therapy analysis Combination therapy analysis Source of business for recently treated patients Persistency and compliance analysis Product-level patient flowcharts
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.
Already a Client? Log in to access this report.
As a Principal Analyst on the Cardiovascular, Metabolic and Renal Disorders team, Gideon has a wealth of experience and expertise in pharmaceutical market analysis. In addition to creating Disease Insights covering metabolic disorders, Gideon has experience in company strategy and portfolio analysis for DRG’s Company & Drug platform. Gideon has a Masters in Biochemistry with Biological Chemistry from the University of Nottingham, and his industry experience dates back to 2009.